Folic acid supplementation in pregnancy and implications in health and disease

Subit Barua*, Salomon Kuizon and Mohammed A Junaid

Abstract
Maternal exposure to dietary factors during pregnancy can influence embryonic development and may modulate the phenotype of offspring through epigenetic programming. Folate is critical for nucleotide synthesis, and preconceptional intake of dietary folic acid (FA) is credited with reduced incidences of neural tube defects in infants. While fortification of grains with FA resulted in a positive public-health outcome, concern has been raised for the need for further investigation of unintended consequences and potential health hazards arising from excessive FA intakes, especially following reports that FA may exert epigenetic effects. The objective of this article is to discuss the role of FA in human health and to review the benefits, concerns and epigenetic effects of maternal FA on the basis of recent findings that are important to design future studies.

Keywords: Folic acid, DNA methylation, Epigenetic, Imprinting, Prenatal nutrition, Neural tube defects, Autism

Introduction
The emerging view of epidemiological studies indicates the importance of the intrauterine environment in early fetal development. With increased understanding of the fundamental mechanism, appropriate DNA methylation including the proper functioning of the epigenetic machinery is highlighted to be essential for embryogenesis and adult health [1-3]. Thus, FA has gained considerable attention because of its promising role in modulating diverse clinical conditions, whereas folate deficiency has been linked with a variety of disorders including birth defects and defects in the development of neural tube closure [4-6]. As stated by Hippocrates nearly 2,500 years ago: “Let food be thy medicine and medicine be thy food” the mandatory FA fortification appears to be a first modern attempt to design a strategy for using food for the prevention or treatment of developmental defects. However, this mandate has resulted in an increase in folate level in the serum to approximately 19 ng/ml, which is above the normal range of the serum folate concentrations in humans i.e. 2.7-17 ng/ml [7]. Epidemiological studies have shown that a significant number of women who took FA supplements during pregnancy exceeded the Institute of Medicine’s recommended tolerable upper limit of 1,000 μg/day. In addition, studies also reported consumption of 400 μg/day of natural food folate plus FA-containing prenatal supplements resulted in supra-nutritional folate status with the greatest increases in pregnant women followed by lactating and non-pregnant women [8,9]. Concern has been raised if such exposure as a result of FA fortification will have any detrimental effects in the general population if not overtly benefit. This review summarizes the beneficial role of folate in human health, the metabolic pathway, epigenetic mechanism and potential concerns based on recent findings.

Folic acid and neural tube defects
Birth defects are one of the major burdens in the human public health with estimates from Centers for Disease Control and Prevention (CDC) approaching 1 in every 33 newborns in the US and accounting for more than 20% of all infant mortalities [10,11]. Neural tube defects (NTDs) are common complex multifactorial disorders in the neurulation of the brain and spinal cord that occurs between 21 and 28 days after conception in humans [12]. Worldwide depending on the ethnic grouping and geographical location, the prevalence has been reported to vary widely between 1 and 10 in every 1000 births or...
established pregnancies [13]. While we are beginning to understand the underlying etiologies, evidence gathered so far implicates both genetic and non-genetic factors such as maternal nutritional status or maternal obesity in the onset of NTDs [14-16]. Over the years, numerous studies including community-based trials often suggested NTDs as vitamin deficiency disorders and have shown that the exogenous or periconceptional supplementation of maternal FA can reduce the risk of NTDs in offspring [17]. Indeed, research spanning decades suggests folate deficiency as a risk factor of NTDs; however the involvement of whole methylation metabolism has also been linked with the etiology of NTDs [16,18,19]. Arguing against the maternal folate deficiency model alone, some studies also reported normal concentrations of folate in the mothers of human fetuses with NTDs. Supporting this, studies in cultured rat embryos or FA deficient mice were reported not to be affected by NTDs as a result of FA deficiency [20-24]. In contrast, studies also reported that exogenous FA and thymidine in the homozygous splotch (Pax3) mouse embryos prevented NTDs and corrected biosynthetic defects [25]. Therefore, no consensus has been reached based on the published data to date. However, as FA deficiency may be a risk factor for NTDs additional studies will be required to determine the mechanistic role of the FA pathway in the onset of neural tube defects.

**History and impact of folic acid on public health**

A possible relationship between apparent folate deficiency and increased incidence of prematurity was suggested as early as 1944 by Callender [26]. This was later confirmed by Gatenby and Lillie [27], and in 1960s, Richard Smithells and Elizabeth Hibbard hypothesized that the under nutrition or impaired folate status could be an important factor in the origin of NTD based on significant observations, that women who had given birth to the children with birth defects i.e. anencephaly and spina bifida have an altered formiminoglutamic acid compared to the women with unaffected children [28]. To test this hypothesis Smithells and his group conducted an intervention trial with supplementation of a multivitamin containing diet with FA 0.36 mg/day during the periconceptional period to the participating women who previously had infants with NTD. In contrast, women who were already pregnant without vitamin supplementation were considered as controls. In the 1980s, they published the results of this multi-center intervention study that revealed about 83-91% reduction in NTD recurrence in supplemented women compared to that of unsupplemented women [29-32]. These results first highlighted that multivitamin or FA supplementation may play a significant role in gestation and may reduce the recurrence of NTD. Later in 1991, after a randomized control trial (RCT) conducted at 33 centers in seven countries, the British Medical Research Council suggested, for women with a previous history of NTD-affected pregnancies, the daily supplementation of 400 micrograms of FA is effective in preventing the recurrence of NTDs by 70% [33]. This was further supported by the results of a RCT conducted in Hungary in 1992 that reported a daily intake of 0.8 mg of FA during the periconceptional period significantly reduced the incidence of a first occurrence of NTD [34]. In 1991, the CDC recommended a daily intake of 4000 µg of FA before and throughout the period of pregnancy for women with prior history of NTD-affected pregnancy [35]. Later in 1998, based on the evidence and recommendation from the wider medical community, the U.S. Public Health Service and Food and Drug Administration recommended mandatory fortifications of FA in flour and grains to prevent NTD and birth defects [36]. In 2007, the Canadian recommendations also included obesity (BMI >35) as a health risk, and recommended “the higher dose FA strategy (5 mg)” in patients with a history of poor compliance with medications and additional lifestyle issues of variable diet, no consistent birth control, alcohol, tobacco, and recreational non-prescription drugs use. Furthermore, to prevent the occurrence of NTDs in epileptic and diabetic mothers the recommendation is to take a higher dose of FA, 4–5 mg/day [37-39].

**Folate metabolism**

FA is central to folate-requiring one-carbon metabolism which play key roles in numerous cellular reactions. These involve amino acid metabolism, biosynthesis of purine and pyrimidine; (the building blocks for DNA and RNA synthesis), and formation of primary methylating agent S-adenosyl-methionine (SAM), which is the universal methyl donor for DNA, histones, proteins and lipids [10]. Mechanistically, the transport of transmembrane folate is facilitated by both receptors and specific carriers active across cell membranes [40]. Under normal circumstances, natural dietary folate is absorbed in the intestine and/or liver and metabolized primarily to 5-methyl tetrahydrofolate (5-methylTHF) and subsequently gets polyglutamated for cellular retention (Figure 1). However, FA consumed in fortified foods/supplements is reduced primarily to dihydrofolate by the enzyme dihydrofolate reductase in the liver and finally converted to the tetrahydrofolate (THF), the substrate for polyglutamate synthetase. The polyglutamyl form of tetrahydrofolate (THF) formed either from FA or normal dietary folate is the central folate acceptor molecule in the one-carbon cycle. Next, THF is converted to 5,10-methyleneTHF by vitamin B6 dependent serine hydroxymethyltransferase and then reduced irreversibly to
5-methylTHF by methylenetetrahydrofolate reductase (MTHFR). 5-Methyl-THF acts as a primary methyl donor for the remethylation of homocysteine to methionine. Methionine is a key substrate for S-adenosylmethionine (SAM) which plays a central role in methylation reactions catalyzed by DNA methyltransferases (DNMTs) forming 5-methylcytosine [41-43]. Thus, the entire FA metabolism is modulated by several folate coenzymes. Mechanistically, the central role of this coenzyme is to modulate the metabolic pathway by accepting or donating one-carbon units [44]. Key genes in this pathway that are involved in transferring the methyl group to homocysteine, and have been most extensively studied include methylenetetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR), reduced folate carrier (RFC), along with vitamin B12-dependent methionine synthase (MTR) [45]. Intriguingly, the etiology of NTDs has long been genetically associated with the dysregulation of the major folate pathway or methionine synthase genes, and single-nucleotide polymorphisms (SNPs) such as 677C > T in the MTHFR gene in humans [25,46]. Thus, further studies on FA induced methylation and detailed analysis of the folate pathway and its role in mammalian neural tube closure could give us more insights in coming years.

**Implications of FA in epigenetic regulation**

The possible impact of nutritional supplements, for example FA, on the mammalian genome can have long lasting effects in human health without any underlying genetic change. The availability of many dietary components involved in one-carbon metabolism including vitamin B6, choline, betaine, methionine, vitamin B12 and folate can result in alterations in the DNA methylation and histone modification. Mechanistically, the modulation of methylation patterns depends on the level of two metabolites of one-carbon metabolism: S-adenosylmethionine (SAM), a methyl donor and S-adenosylhomocysteine (SAH), a product inhibitor of methyltransferases [47-49]. Thus, nutrient epigenetic factors such as FA, a cofactor in one-carbon metabolism during gestation can affect the fetal programming and may modulate the genome-wide methylation pattern of DNA and cause dysregulation in the expression of genes [50]. The epigenetic impact of FA along with other one-carbon metabolites is best studied in the agouti mouse (*Avy*) experiment that has shown that the dietary methyl donors, including FA, has no affect on the *Avy* methylation in the mother but clearly affected the *Avy* methylation and phenotype of developing offspring [51]. Similar to the animal study, a study in young children from mothers having periconceptional FA of 400 μg per day was shown to have enrichment in the methylation of maternally imprinted insulin-like growth factor 2 gene (IGF2) compared to those with no periconceptional maternal FA [52]. In addition, several epidemiologic and molecular evidences also link folate supplementation and epigenetic alteration by DNA methylation with neural growth and recovery, including the activation of folate receptor (Folr1), in spinal cord regeneration [53,54]. In an attempt to understand the FA induced epigenetic mechanism to rescue neural tube closure, a recent study in Splotch embryos (*Sp−−*) has also shown that
maternal intake of folate prior to conception decreases the H3K27 methylation marks and remodels the chromatin on Hes1 and Neurog2 promoters, genes that are essential for neural tube development [55]. Recently, our study has shown that FA supplementation dysregulates expressions of several genes including FMR1 in lymphoblastoid cells [56], and a follow up study in a mouse model has also identified widespread alteration in the methylation pattern of the brain epigenome in offspring from high maternal FA during gestation [57]. The alterations in the methylation pattern were exhibited both in CpG and non-CpG regions resulting in differences in the expression of several key developmental and imprinted genes. In addition, we also found that the methylation and expression of several genes are altered in a gender-specific manner. Thus, it is clear that folate plays a key role in epigenetic regulation of fetal developmental programming. In the future, more studies on the role of folate deficiency or over supplementation on epigenetic alterations will establish causality of the amount of FA and DNA methylation in diseases.

Folate intake and concern about potential adverse effect
The clinical significance of the chronic or high intake of FA is not well established. Post fortification epidemiological studies have reported an increase of approximately twice the amount in the intake of FA than previously projected. Concern has been raised regarding the potential health effects, since in addition to the fortified products there is prevalence of using widespread supplementation including over-the-counter prenatal vitamins as well as energy drinks which are substantially enriched with various vitamins [58-59]. Recently, our study in the mouse model has found that ten-fold increase in maternal FA supplementation during gestation altered the expression of several genes in the frontal cortex of day old pups [60]. Moreover, continuation of such higher amounts of FA throughout the post-weaning period exhibited alterations in behaviors compared to offspring from mothers having lower doses of gestational FA supplementation. Mechanistically, such changes of behavioral outcomes may possibly result from alterations of gene expression as a result of aberrant methylation.

Intriguingly, results from several studies also suggested that folate supplementation can induce aberrant patterns of DNA methylation, and mechanistically may play a dual role in carcinogenesis. FA supplementation may prevent the early lesions, or potentially harm by enhancing the progression of established preneoplastic lesions [61]. Studies in rodent models - have shown that supplementation of FA promotes the progression of mammary tumor, and supporting this view a study in a genetically engineered mouse model of a human cancer has shown that FA deficiency during the peri-gestational period protects or decreases medulloblastoma formation [62,63]. However, a meta-analysis of data conducted on 50,000 individuals to assess the effects of FA found that FA supplementation does not substantially increase or decrease incidence of site-specific cancer during the first 5 years of treatment (RR = 1.06, 95% CI 0.99-1.13) in comparison to placebo [64]. Moreover, a study from children participating in the Northern California Childhood Leukemia Study (NCCLS) further revealed no significant association of folate concentration at birth with childhood acute myeloid leukemia (Additional file 1: Table S1). In contrast, several RCT and meta-analyses have reported that prenatal multivitamins containing FA - are associated with a significant protective effect on pediatric cancers: leukemia, pediatric brain tumors and neuroblastoma [65], (Additional file 1: Table S1).

In addition, recent ecological studies provided support for a decrease in Wilms tumour, neuroblastoma, primitive neuroectodermal tumours and ependymomas after Canadian and United States FA fortification [66,67], (Additional file 1: Table S1).

Although controversial, over-supplementation is also reported to be involved in certain chronic disease and found not to reduce cardiovascular disease [68,69]. In addition, acute folate intake is also found to result in significant down-regulation of folate transporters in kidney, and thus dysregulated the renal folate uptake process [70]. Moreover, several RCT and observational studies suggested that maternal intake of multivitamins including FA during pregnancy may modulate pregnancy related outcomes [71-75] including developmental outcome of offspring (Additional file 1: Table S1).

The causal link between the maternal FA supplementation and the development of childhood asthma has been of interest as asthma is considered to be an interaction of both genetic and environmental risk factors, and concern has arisen as epidemiological studies have also shown that increased folate in pregnancy may influence poor respiratory health in children [76,77]. Several studies, including RCT and observational studies were conducted to reveal such associations, however conflicting results were found in these studies. While some studies found positive association between FA exposure and increase in risk of childhood asthma, other studies found no such association (Additional file 1: Table S1).

In addition, studies in humans, also reported to have found higher blood folate concentration of unmetabolized FA and naturally occurring folates [78].

To gain a better understanding if maternal supplementation of FA modulates pregnancy related outcomes, much focus has been given to reveal the role of FA supplementation in the increased incidence of dizygotic twinning. This followed after the report of a Swedish study suggested a possible association of FA supplementation with the increase in the twinning rate [79]. A meta-
analysis using the Food Standards Australia New Zealand (FSANZ) framework by Muggli et al. [80] has suggested that the hypothesis of the increase in dizygotic twins is still to be demonstrated (OR = 1.26, 95% CI 0.91-1.73 for pre-conceptional supplementation and dizygotic twins; OR = 1.02, 95% CI 0.85-1.24 for overall twins), and, if true, it would only cause a very limited increase. However, Berry et al. reported that the association of FA with an increase in dizygotic twining as reported by the Swedish study has probably led to false findings based on the reported 40% misclassification of the use of in vitro fertilization [81]. This was further supported by a Norwegian study that found no evidence for an association between preconceptional folate supplements and twinning after exclusion of known in vitro fertilization pregnancies, and accounting for under-reporting of both in vitro fertilization pregnancies and folate use [82].

Thus it is clear that FA intake during pregnancy and during daily life plays a significant role in modulating gene expression and disease related outcome. Considering the important role of FA in several cellular process, including epigenetic modulation and reducing the incidence of NTDs (Additional file 1: Table S1), the dose, timing (pre-conceptional/peri-conceptional/in-pregnancy), and source of folate intervention during pregnancy and throughout the life time may be critical. In the future, more clinical and basic studies to decipher the link between over supplementation and normal development will help us to understand the discordances between benefit and possible harm.

Maternal folate intake and health outcomes in children - a brief systemic review of recent cohorts study

For a better understanding of the effect of maternal FA, we systematically reviewed recent published literature (2011–2014) in order to assess the outcome of maternal FA supplementation on the health of newborn infants [83-134] (Additional file 1: Table S1). While results of several cohort and observational studies in USA, Canada, Chile, Australia, several countries in Europe and Asia have reported the clinical significance of FA supplementation, the direction of the beneficial effect was not in favorable terms in all the cases. Therefore, several countries have mandatory regulated FA fortifications, and despite its efficacy there is no universal agreement based on the published data to date [135]. The concern regarding the appropriate dose and potential side effects are still a matter of debate [16,136]. As maternal FA can induce potential epigenetic effects on the genome of the offspring which may vary with the metabolic ability of individual race, sex, geographical locations or interactions with other nutrients, one possible reason of inconsistency between studies may be due to differences in the design of the study. In the future there is definitely a need of global collaboration to accumulate scientific evidence from a clinical perspective, and to interpret these intervention studies and potential effect in large cohorts.

Figure 2 A representative integrative model of possible epigenetic influence on pregnancy outcomes. Maternal intake of FA may result in epigenetic modulation in the offspring brain methylome with overall or site specific alterations of methylation in genomic DNA, non-coding RNA and histone modifications. These effects may alter gene expression of several imprinted, candidate autism susceptibility and key developmental genes. Such changes may impact other biological processes, and associate with the overall developmental outcome. Scientific artwork adapted from [137,138].
Conclusion
The clinical application of FA supplementation/intake to prevent NTDs has been well proven for the last 20–25 years (Additional file 1: Table S1). However considering the concern with the level of folate concentration following post-fortifications, it is of interest to explore if FA exposure in significant sections of the population is influencing other normal biological processes, such as the brain’s development (Figure 2). Determining the level and distribution of the methylation profile of the brain epigenome may reveal the mechanism and downstream consequences of various neuropsychiatric and impaired disorders including autism. Moreover as the level of folate status can influence methylation, in the future more studies are needed to explore the systemic differences in the DNA methylation profile in relation to timing and dose between different populations and between genders. Studies and careful monitoring of the consequences of FA intake in global perspectives will help clinicians to determine a proper therapeutic strategy and the best preventive measures to improve the overall public health, moreover to precisely differentiate the evaluation of this vitamin in nutrition, in fortification and in supplementation.

Additional file

Additional file 1: Table S1. Studies of maternal folate intake and health outcomes in children.

Abbreviations
FA: Folic acid; NTD: Neural tube defect; CDC: Centers for disease control and prevention; RCT: Randomized control trial; SAM: S-adenosyl- methionine; SAH: S-adenosylhomocysteine; DNMTs: DNA methyltransferase; 5-methylTHF: 5-methyl tetrahydrofolate; THF: Tetrahydrofolate; MTHFR: Folic acid metabolism and human epigenetics. Am J Clin Nutr 2011, 93:1172–1177.
4. Smithells RW, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM: Folate status response to a controlled folate intake in nonpregnant, pregnant, and lactating women. Am J Clin Nutr 2012, 96:789–800.
5. Wallingford JB, Niswander LA, Shaw GM, Finnell RH: The fundamental challenge of understanding, preventing, and treating neural tube defects. Science 2013, 339:1222002.
6. Blom HJ, Molloy MA: Folic acid, methylation and neural tube closure in humans. Birth Defects Res C Mol Teratol 2009, 85:295–302.
7. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM: Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. J Med Genet 1993, 30:702–708.
8. Scott JM: Folate and vitamin B12. Proc Nutr Soc 1999, 58:441–448.
9. Scott JM, Weir DG, Molloy A, McPartlin J, Daly L, Kirke P: Folic acid metabolism and mechanisms of neural tube defects. Ciba Found Symp 1994, 181:180–187.
10. Heik MD, Bills ND, Hinrichs SH, Clifford AJ: Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010, CD007950.
11. Vandevijvere S, Amsalkhir S, Van Oyen H, Moreno-Reyes R: Folic acid, methylation and mechanisms of neural tube defects. Eur J Obstet Gynecol Reprod Biol 1998, 78:9–16.
12. Smithells RW, Sheppard S, Wild J, Schorah CJ: Determinants of folate status in pregnant women; results from a national cross-sectional survey in Belgium. Eur J Clin Nutr 2012, 66:1172–1177.
13. Smithells RW, Sheppard S, Schorah CJ: Folic acid in nutrition, in fortification and in prevention of neural-tube-defect recurrences. Int J Epidemiol 1979, 7:686–690.
14. Imbard A, Benoist JF, Blom HJ: Folic acid metabolism and human epigenetics. Am J Clin Nutr 2011, 93:1172–1177.
15. Frey L, Hauser WA: Epidemiology of neural tube defects. Epilepsia 2003, 44(Suppl 3):A–13.
16. Imbard A, Benoist JF, Blom HJ: Neural tube defects, folate acid and methylation. Int J Environ Res Public Health 2013, 10:4352–4389.
17. De Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP: Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010, CD007950.
18. Vandevijvere S, Amsalkhir S, Van Oyen H, Moreno-Reyes R: Folinic acid in nutrition, in fortification and in prevention of neural-tube-defect recurrences. Int J Epidemiol 1979, 7:686–690.
19. Smithells RW, Sheppard S, Schorah CJ: Folic acid in nutrition, in fortification and in prevention of neural-tube-defect recurrences. Int J Epidemiol 1979, 7:686–690.
20. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM: Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. J Med Genet 1993, 30:702–708.
21. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM: Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. J Med Genet 1993, 30:702–708.
22. Scott JM: Folate and vitamin B12. Proc Nutr Soc 1999, 58:441–448.
23. Scott JM, Weir DG, Molloy A, McPartlin J, Daly L, Kirke P: Folic acid metabolism and mechanisms of neural tube defects. Ciba Found Symp 1994, 181:180–187.
24. Heik MD, Bills ND, Hinrichs SH, Clifford AJ: Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010, CD007950.
25. Frey L, Hauser WA: Epidemiology of neural tube defects. Epilepsia 2003, 44(Suppl 3):A–13.
26. Imbard A, Benoist JF, Blom HJ: Neural tube defects, folate acid and methylation. Int J Environ Res Public Health 2013, 10:4352–4389.
27. De Regil LM, Fernandez-Gaxiola AC, Dowswell T, Pena-Rosas JP: Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010, CD007950.
28. Vandevijvere S, Amsalkhir S, Van Oyen H, Moreno-Reyes R: Folinic acid in nutrition, in fortification and in prevention of neural-tube-defect recurrences. Int J Epidemiol 1979, 7:686–690.
29. Smithells RW, Sheppard S, Wild J, Schorah CJ: Determinants of folate status in pregnant women; results from a national cross-sectional survey in Belgium. Eur J Clin Nutr 2012, 66:1172–1177.
30. Smithells RW, Sheppard S, Wild J, Schorah CJ: Determinants of folate status in pregnant women; results from a national cross-sectional survey in Belgium. Eur J Clin Nutr 2012, 66:1172–1177.
31. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW: Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980, 315:339–340.
32. Wald NJ: Commentary: a brief history of folic acid in the prevention of neural tube defects. Int J Epidemiol 2011, 40:1154–1156.
33. MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991, 338:131–137.
34. Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992, 327:1632–1635.
35. Centers for Disease Control (CDC): Use of folic acid for prevention of spina bifida and other neural-tube defects—1983-1993. MMWR Morb Mortal Wkly Rep 1991, 40:503–516.
36. Crandall BF, Corson VL, Evans MI, Goldberg JD, Knight G, Salafsky IS: American College of Medical Genetics statement on folic acid: fortification and supplementation. Am J Med Genet 1998, 78:381.
37. Wilson RD, Johnson JA, Wyatt P, Allen V, Gagnon A, Langlois S, Bigelow C, Audibert F, Desilets V, Brock JA, Koren G, Goh YL, Nguyen P, Kapur B: Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2007, 29:1003–1026.
38. Kennedy D, Koren G: Identifying women who might benefit from higher doses of folic acid in pregnancy. Can Fam Physician 2012, 58:394–397.
39. Wald NJ, Law MR, Morris JK, Wald DS: Folate and one-carbon metabolism and its impact on nutrition. Biochem Biophys Res Commun 2011, 412:688–692.
40. Wald NJ, Law MR, Morris JK, Wald DS: Folate and one-carbon metabolism and its impact on nutrition. Biochem Biophys Res Commun 2011, 412:688–692.
41. Barua S, Kuzson K, Chadman KK, Flory MJ, Brown WT, Jundai MA: Single-base resolution of mouse offspring brain methylene reveals epigenome modifications caused by gestational folic acid. Epigenetics Chromatin 2014, 7:3.
42. Cheumrunkitwach SF, Selhub J, Wilson PW, Radder JL, Rosenberg IH, Jacques PF: Folic acid intake from fortification in United States exceeds predictions. J Nutr 2012, 132:2792–2798.
43. Ly A, Lee H, Chen J, Sie KK, Renlund R, Medline A, Sohn KJ, Croxford R, Thompson LU, Kim Y: Effect of maternal and postweaning folic acid supplementation on mammary tumor risk in the offspring. Cancer Res 2011, 71:988–997.
44. Barua S, Chadman KK, Kuzson K, Buenaventura D, Stapley MW, Rucco F, Bergum U, Guariglia SR, Brown WT, Jundai MA: Increasing Maternal or Post-Weaning Folic Acid Alters Gene Expression and Moderately Changes Behavior in the Offspring. PLoS One 2014, 9:e101674.
45. Hoffmann DR, Marion DW, Comarow TE, Duerr JA: S-Adenosylhomocysteine and S-adenosylhomocysteine metabolism in isolated rat liver. Effects of genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLoS One 2013, 8:e59570.
46. Molyo AM, Brody LC, Mills J, Scott M, Kikie PN: The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res C Mol Teratol 2009, 85:285–294.
47. Hoffman DR, Marion DW, Comarow TE, Duerr JA: S-Adenosylhomocysteine and S-adenosylhomocysteine metabolism in isolated rat liver. Effects of genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLoS One 2013, 8:e59570.
48. Molloy AM, Brody LC, Mills J, Scott M, Kikie PN: The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res C Mol Teratol 2009, 85:285–294.
49. Hoffmann DR, Marion DW, Comarow TE, Duerr JA: S-Adenosylhomocysteine and S-adenosylhomocysteine metabolism in isolated rat liver. Effects of genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLoS One 2013, 8:e59570.
50. Molloy AM, Brody LC, Mills J, Scott M, Kikie PN: The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res C Mol Teratol 2009, 85:285–294.
51. Hoffman DR, Marion DW, Comarow TE, Duerr JA: S-Adenosylhomocysteine and S-adenosylhomocysteine metabolism in isolated rat liver. Effects of genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLoS One 2013, 8:e59570.
52. Molloy AM, Brody LC, Mills J, Scott M, Kikie PN: The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res C Mol Teratol 2009, 85:285–294.
53. Hoffman DR, Marion DW, Comarow TE, Duerr JA: S-Adenosylhomocysteine and S-adenosylhomocysteine metabolism in isolated rat liver. Effects of genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLoS One 2013, 8:e59570.
54. Molloy AM, Brody LC, Mills J, Scott M, Kikie PN: The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res C Mol Teratol 2009, 85:285–294.
75. Alwan NA, Greenwood DC, Simpson NA, McArndle HJ, Cade JE. The relationship between dietary supplement use in late pregnancy and birth outcomes: a cohort study in British women. BOCG 2010, 117:821–829.

76. Whitrow MJ, Moore VM, Rumbold AR, Davies MJ. Effect of supplemental folic acid in pregnancy on childhood asthma: a prospective birth study. Am J Epidemiol 2009, 170:1485–1493.

77. Haberg SE, London SJ, Sigture H, Naftstad P, Nystad W. Folic acid supplements in pregnancy and early childhood respiratory health. Arch Dis Child 2009, 94:180–184.

78. Smith AD, Kim Y, Refsum H: Is folic acid good for everyone? Am J Clin Nutr 2008, 87:517–533.

79. Kallen B: Use of folic acid supplementation and risk for dizygotic twinning. Early Hum Dev 2004, 80:143–151.

80. Muggli EE, Halliday JL. Folic acid and twin pregnancies. A systematic review of the literature, July 1994 to July 2006. Med J Aust 2007, 186:234–248.

81. Berry RJ, Kilbberg R, Devine O: Impact of misclassification of in vitro fertilisation in studies of folic acid and twinning: modelling using population based Swedish vital records. BMJ 2005, 330:815.

82. Volfse SE, Gensing HK, Tandberg A, Ronning T, Ingens LM, Baste V, Nilsen RA, Dalveit AK. Folate supplementation and twin pregnancies. Epidemiology 2005, 16:201–205.

83. Parker SE, Yazdy MM, Tinker SC, Mitchell AA, Werler MM: Folic acid intake and spina bifida. Am J Obstet Gynecol 2013, 209:236e1-8.

84. Ahrens K, Yazdy MM, Mitchell AA, Werler MM: Folic acid intake and spina bifida in the era of dietary folic acid fortification. Epidemiology 2011, 22:731–737.

85. Conte F, Mellado C, Bortolus R, Franchi M. Preconception folic acid supplementation and risk for chromosome 21 nondisjunction: a report from the National Down Syndrome Project. Am J Med Genet A 2013, 15:1438–444.

86. Bean LJ, Magnus P, Reichborn-Kjennerud T, Schjolberg S, Davey SG, Oyen AS, Mantovani E, Filippini F, Berti C, Trovato M, Lohner S, Dullemeijer C, Souverein OW, Cetin I, Pastor-Valero M, Navarrete-Munoz EM, Rebagliato M, Iniguez C, Murcia M, Fekete K, Bhat S, Kurpad AV, Jovanovic V, Tassone F, Hertz-Picciotto I, Chakraborty H, Souza J, Pereira R, Padvanov T, Moret-Feletre D, Murray J. High dosage folic acid augmentation in pregnancy: a randomised clinical trial. BJOG 2012, 119:115–122.

87. Borja-Aburto VH, Covington T, Soto-Estrada J, Vargas-Diego S, Escalante-Garcia R, Estrada-Rivas R, dinneringen N, Kopp S, Veugelers PJ. Folate use and nonsyndromic orofacial clefts in China: a prospective cohort study. Epidemiology 2012, 23:423–432.

88. Imdad A, Yakoob MY, Bhutta ZA. Folate use and nutrition: a review of the recent literature, July 1994 to July 2006. Nutr J 2007, 6:51.

89. Romitti PA, Royle MH, Torfs CP, Freeman SB, Sherman BM, Folic acid supplements in Down syndrome: a report from the National Down Syndrome Cooperative Study. Congenit Anom (Kyoto) 2004, 43:180–186.

90. Dwarkanath P, Barzilay JR, Thomas T, Thomas A, Bhat S, Kurpad AV, Li S, Chao A, Li Z, Moore CA, Liu Y, Zhu J, Erickson JD, Hao L, Berry RJ: Folic acid use and nonsyndromic orofacial clefts in Crete, Greece (Rhea study). Birth Defects Res A Clin Mol Teratol 2013, 97:570–577.

91. Li X, Li S, Mu D, Liu Z, Li Y, Lin Y, Chen X, You F, Li N, Deng K, Deng Y, Wang Y, Zhu J. The association between periconceptional folic acid supplementation and congenital heart defects: a case–control study in China. Prev Med 2013, 56:385–389.

92. Rozenblatt AM, Van Ersen AJ, Te Meereman GJ, Bakker MK, van der Biezen JJ, Goorhuis-Brouwer SM, Vermeij-Keers C, De Walle HE. Periconceptional folic acid associated with an increased risk of oral clefts relative to non-folate related malformations in the Northern Netherlands: a population based case–control study. Eur J Epidemiol 2013, 28:875–887.

93. Wla-Nova C, Wehby GL, Queiros FC, Chakraborty H, Felix TM, Goco N, Moore J, Gewehv ER, Lins A, Affonso CM, Murray JC. Periconceptional use of folic acid and risk of miscarriage: findings of the Oral Cleft Prevention Program in Brazil. J Perinat Med 2013, 41:461–466.

94. Wehby GL, Felix TM, Goco N, Richieri-Costa A, Chakraborty H, Souza J, Pereira R, Padvanov T, Moret-Feletre D, Murray J. High dosage folic acid supplementation, oral cleft recurrence and fetal growth. Int J Environ Res Public Health 2013, 10:590–605.

95. Kelly D, O'Dowd T, Reulbach U. Use of folic acid supplements and risk of cleft lip and palate in infants: a population-based cohort study. Br J Gen Pract 2012, 62:465–467.

96. Li S, Chao A, Li Z, Moore CA, Liu Y, Zhu J, Erickson JD, Hao L, Berry RJ: Folic acid use and nonsyndromic orofacial clefts in Crete, Greece (Rhea study). Birth Defects Res A Clin Mol Teratol 2013, 97:570–577.
and anthropometric measures at birth in a cohort of pregnant women in Valencia, Spain. Br J Nutr 2011, 105:1352–1360.

116. Der Woude PA Z-v, De Walle HE, Hoek A, Bos HI, Boezen HM, Koppelman GH, Den Berg LT DJ-v, Scholten S: Maternal high-dose folate during pregnancy and asthma medication in the offspring. Pharmaceutics 2014.

117. Veeranki SP, Gebretsadik T, Dorris SL, Mitchell EF, Hartert TV, Cooper WQ, Tylavsky FA, Dupont W, Hartman TJ, Carroll KN: Association of folic acid supplementation during pregnancy and infant bronchiolitis. Am J Epidemiol 2014, 179:938–946.

118. Brown SB, Reeves KW, Bentz-Elizer DR, Berry RJ: Prenatal folate and risk of asthma in children: a systematic review. Nutr Rev 2014, 72:65–64.

119. Crider KS, Cordero AM, Qi YP, Mulinare J, Dowling NF, Berry RJ: Prenatal folic acid and risk of asthma in children: a systematic review and meta-analysis. Am J Clin Nutr 2013, 98:1272–1281.

120. Bekkers MB, Elstgeest LE, Scholten S, Haverman-Nies A, De Jongste JC, Kerkhof M, Koppelman GH, Gehring U, Smit HA, Wijga AH: Maternal use of folic acid supplements during pregnancy, and childhood respiratory health and atopy. Eur Respir J 2012, 39:1468–1474.

121. Kiefte-de Jong JC, Timmermans S, Jaddoe VW, Hofman A, Tiemeier H, Steegers EA, De Jongste JC, Moll HA: High circulating folate and vitamin B-12 concentrations in women during pregnancy are associated with increased prevalence of atopic dermatitis in their offspring. J Nutr 2012, 142:731–738.

122. Dunstan JA, West C, McCarthy S, Metcalfe J, Meldrum S, Oddy WH, Tulic MK, D’Vaz N, Prescott SL: The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhood. Allergy 2012, 67:50–57.

123. Martenssen MP, Risnes KR, Jacobsen GW, Bracken MB: Folic acid supplementation in early pregnancy and asthma in children aged 6 years. Am J Obstet Gynecol 2012, 206:72–77.

124. Magdelijns FJ, Mommers M, Penders J, Smits L, Thijis C: Folic acid use in pregnancy and the development of atopy, asthma, and lung function in childhood. Pediatrics 2011, 128:e135–e144.

125. Sharland E, Montgomery B, Granell R: Folic acid in pregnancy - is there a link with childhood asthma or wheeze? Aust Fam Physician 2011, 40:421–424.

126. Haberg SE, London SJ, Nafstad P, Nilsen RM, Ueland PM, Vollset SE, Nystad W: Maternal folate levels in pregnancy and asthma in children at age 3 years. J Allergy Clin Immunol 2011, 127:262–264.

127. McNulty B, McNulty H, Marshall B, Ward M, Mollov AM, Scott JM, Dornan J, Pentieva K: Impact of continuing folic acid after the first trimester of pregnancy: findings of a randomized trial of Folic Acid Supplementation in the Second and Third Trimesters. Am J Clin Nutr 2013, 98:92–98.

128. Hoyos C, Munthe AP, Schildkraut JM, Jirtle RL, Dønemark-Wahnefried W, Forman MR, Versen ES, Kurtzberg J, Overcash F, Huang Z, Murphy SK: Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy. Epigenetics 2011, 6:928–936.

129. Greenop KR, Miller M, De Klerk NH, Scott RJ, Attia J, Ashton LJ, Dalla-Pozza L, Bower C, Armstrong BK, Milne E: Maternal dietary intake of folate and vitamins B6 and B12 during pregnancy and risk of childhood brain tumors. Nutr Cancer 2014, 66:800–809.

130. Chokkalingam AP, Chun DS, Noonan EJ, Pfeiffer CM, Zhang M, Month SR, Taggart DR, Wiemels JL, Metayer C, Buffler PA: Blood levels of folate at birth and risk of childhood leukemia. Cancer Epidemiol Biomarkers Prev 2013, 22:1086–1094.

131. Orjuela MA, Cabrera-Munoz L, Paul L, Ramirez-Ortiz MA, Liu X, Chen J, Mejia-Rodriguez F, Medina-Sanson A, Diaz-Carreno S, Suen IH, Selhub J, Ponce-Castaneda MV: Risk of retinoblastoma is associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake. Cancer 2012, 118:5912–5919.

132. Milne E, Greenop KR, Bower C, Miller M, Van Bockemer FM, Scott RJ, De Klerk NH, Ashton LJ, Gottardo NG, Armstrong BK: Maternal use of folic acid and other supplements and risk of childhood brain tumors. Cancer Epidemiol Biomarkers Prev 2012, 21:1933–1941.

133. Armingou A, Rustad J, Orsi L, Gujon-Bellec S, Leverger G, Baruchel A, Bertrand Y, Nelken B, Plat G, Michel G, Haouy S, Chatagner P, Ducassou S, Rialland X, Hemon D, Clavel J: Folic acid supplementation, MTHFR and MTRR polymorphisms, and the risk of childhood leukemia: the ESCALE study (SFCE). Cancer Causes Control 2012, 23:1265–1277.